Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14692)	9/17/2000 1:04:58 PM
From: Cacaito	Respond to of 17367

"underpowered" due to the number of subjects, same results with 1500 subjects will be enough (quick guess, calculations at some point later). If the ethical reason around "informed consent" could be work around, still must probably a 2 to 3 hour delay will happen, then it will operate the same for placebo, and then many of the 53 deaths not in the study will be in and then the mortality will be proportionally about the SAME, cause is not your wish operating is REALITY. And the delay with more subjects could be overcome easier, cause one will have more subjects that are at the "salvage" stay, and not just quick treatment (and quick death anyway) of the ones at the "point of no return". It works both ways pro/con. The six hour delay is not an excuse.